Catalent Brass Face Investor Suit Over COVID Vaccine Woes
The top brass of pharmaceutical company Catalent Inc. face a shareholder derivative suit in Delaware federal court over claims they lied to investors about the health of the company's finances and...To view the full article, register now.
Already a subscriber? Click here to view full article